BÜHLMANN Laboratories AG today announced the appointment of Eric Hrimech to the newly created position of global Chief Commercial Officer (CCO).
The CCO position has been established to significantly expand BÜHLMANN’s go-to-market capabilities, delight our customers with our cutting-edge products and services, and accelerate our full market potential. Global sales, marketing, customer service, and our international subsidiaries will all report into the CCO. This structure will enable rapid and impactful commercial decision making.
Eric Hrimech has over 20 years of global experience in the in-vitro diagnostics and medical technology sectors, with senior leadership roles at Siemens Healthineers, Abbott, and Covidien. Throughout his career, he has consistently driven increased competitiveness and profitable growth across diverse markets. Most recently, he has been advising private equity firms on M&A projects, market expansion, and commercial strategy. He holds a master’s degree in biochemistry, completed doctoral studies in microbiology and immunology, pursued post-doctoral research in biochemistry, and earned an MBA in bio-industries.
Eric Hrimech will start his new role at BÜHLMANN Laboratories on May 5, 2025. Please join me in welcoming Eric into this new role. He will reach out to many of you soon, and we appreciate your ideas and support for achieving our ambitious growth targets.
Donal Quinn, chairman of the BÜHLMANN Laboratories Advisory Board, says: “May 5, 2025, is a very significant milestone for BÜHLMANN Laboratories AG. In addition to Christian Eberle joining us as new CEO, Christian and I have the honor of welcoming Eric as an outstanding executive to BÜHLMANN. I know that our customers, employees, and owners will benefit enormously from having Eric as a key member of the BÜHLMANN team”.
Social Links